Ativo Capital Management’s AstraZeneca AZN Stock Holding History

Ativo Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,460	Closed	-$263K	–	116
2018 Q4	$263K	Sell	3,460 -490	-12%	-$38.3K	0.12%	116
2018 Q3	$313K	Hold	3,950	–	–	0.08%	204
2018 Q2	$277K	Hold	3,950	–	–	0.08%	219
2018 Q1	$276K	Hold	3,950	–	–	0.08%	212
2017 Q4	$274K	Hold	3,950	–	–	0.07%	210
2017 Q3	$268K	Hold	3,950	–	–	0.07%	212
2017 Q2	$269K	Buy	+3,950	New	+$258K	0.07%	217
2016 Q4	–	Sell	-33,151	Closed	-$2.18M	–	222
2016 Q3	$2.18M	Buy	+33,151	New	+$2.17M	0.5%	59
2014 Q2	–	Sell	-32,497	Closed	-$2.11M	–	165
2014 Q1	$2.11M	Sell	32,497 -2,368	-7%	-$153K	0.86%	43
2013 Q4	$2.07M	Sell	34,865 -375	-1%	-$20.4K	0.91%	38
2013 Q3	$1.83M	Sell	35,240 -1,625	-4%	-$81.6K	0.87%	44
2013 Q2	$1.74M	Buy	+36,865	New	+$1.88M	0.9%	47

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ativo Capital Management's AZN Position: Q1 2019 in Review

Ativo Capital Management sold out of AstraZeneca (AZN) in Q1 2019, closing a stake of 3,460 shares — an estimated $263K sold.

Ativo Capital Management first reported a position in AZN in Q2 2013 and held it in 12 quarters. The position peaked at $2.18M in Q3 2016. 561 funds tracked by Wall St. Rank hold AZN as of Q1 2019.

Ativo Capital Management reported no remaining AstraZeneca position as of Q1 2019 after selling out during the quarter.
Ativo Capital Management sold 3,460 AstraZeneca shares in Q1 2019, an estimated $263K.
Ativo Capital Management first reported a position in AstraZeneca in Q2 2013 and held it in 12 quarters.
Ativo Capital Management's AstraZeneca position peaked at $2.18M in Q3 2016.
561 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2019.

Based on Ativo Capital Management's 13F filing for Q1 2019, filed 14 May 2019.